Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
about
Optimizing the management of advanced non-small-cell lung cancer: a personal viewChemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancerNon-small cell lung cancer: current treatment and future advancesIs there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesImmune Checkpoint Blockade in Cancer TherapyEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer50 Years of progress in the systemic therapy of non-small cell lung cancerClinical Translation of Nanomedicine.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer.Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancerPhase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.Phase I trial of nedaplatin and paclitaxel for patients with non-small cell lung cancer.First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)Vorinostat in solid and hematologic malignanciesPhase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.Comparison of vinorelbine-Cisplatin with gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer.First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancernab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.[A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trialsEfficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association grouCost analysis with censored dataAntitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer modelCurrent state of immunotherapy for non-small cell lung cancer.U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancerManagement of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapyTargeting the eicosanoid pathway in non-small-cell lung cancer.Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer.Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: a single institute study.Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized MedicineLiposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial.
P2860
Q24656144-5D939447-DC69-4148-9E5D-2759B6058268Q24792196-DEDE719C-E611-4A75-9437-54D9290C7FCAQ24799908-D09C2C3C-F7E8-4062-B242-BE2A4B7DDAC3Q26740333-570D3C1C-38BD-441C-9E41-769A7E7440AFQ26766180-3B085EDF-9A83-4393-BC8C-CA2E2C5961C1Q26830509-EC9303F5-9D4C-4CA5-B715-AA08519908C1Q26852507-8310D195-2DBC-4159-A234-225F0C8B1E07Q27014978-3023632B-75F9-4BBD-9C9C-704FB9F102A1Q30355939-D76BB2C6-022E-47AC-AC63-A0B5D02E38E1Q30438068-71ECCCCB-14A7-4636-8991-F0B9434E3B71Q33343275-66CAB266-989F-4A77-A78B-38FBDC4FF63DQ33360013-C2379538-4E33-4695-8ADA-D9A3E80B9639Q33360840-FC87B9BD-A6F1-470C-A786-B263A919027DQ33366782-652713ED-27DF-4B23-A448-E1E3346E73AEQ33369413-35ACC7A7-5D2A-4BB3-BE1C-47EAF40310BBQ33373493-49FFE927-4F6C-4E6F-8993-EF3B7C105DDEQ33375704-FF0F9BD0-F910-4AE4-9863-B07AAAD6D5A3Q33382525-878FD9A6-D99C-4EF5-B3E1-422370B2AE80Q33385544-9E0701CC-686F-46FC-9386-EED5DE77E976Q33387995-BE7E691A-0AD7-4503-920A-9A9AAB39ABD1Q33393287-0E99BA7E-8AD6-4F21-862D-BD5697284FD5Q33401434-5F684E85-91A8-4C22-8C07-6C33E9C13653Q33402690-CA07D737-18DD-4FAC-8A27-7B2CE3464D32Q33412928-011242B0-B70C-4C2F-A34B-71BCD8F6EABDQ33414806-9B76EABF-F92D-4DAA-8308-9C999B920AF6Q33436415-A8B5720B-F36A-4545-927B-3DF8D6A2F553Q33442591-466D7B61-CF07-4F71-8980-4A5FD9C54054Q33470189-8586C1E4-4DB2-4350-805E-27CEC11FCA52Q33575434-D8801F81-ADCB-4F04-A543-E3547BE35CE4Q33645595-61D6752D-D000-4F92-B4DD-574896287B91Q33829794-094878D7-422C-43BE-9813-922535E22956Q33834851-C9796649-150B-4367-99C8-F80A206DC48FQ33885578-365D2911-2277-4B0C-A96D-3403B5F24164Q33936807-B201ECA6-BE04-4514-85BB-10ED02C28085Q34001991-7C321D0A-9B10-412F-822E-B24C4379642DQ34005272-271FF0B5-D1FB-41F5-99F0-F13F595C7DDDQ34040130-838589B7-29BF-462F-8AFA-CF2E3BBD5847Q34146137-5AB025BD-6C14-4CFD-AFED-53251DB2EC59Q34219452-DEFC564C-437D-4922-B084-E8A6DCDEB45BQ34231106-66916A1D-AD29-485E-8C5F-49A2550E51F0
P2860
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Randomized phase III trial of ...... outhwest Oncology Group trial.
@en
Randomized phase III trial of ...... outhwest Oncology Group trial.
@nl
type
label
Randomized phase III trial of ...... outhwest Oncology Group trial.
@en
Randomized phase III trial of ...... outhwest Oncology Group trial.
@nl
prefLabel
Randomized phase III trial of ...... outhwest Oncology Group trial.
@en
Randomized phase III trial of ...... outhwest Oncology Group trial.
@nl
P2093
P1476
Randomized phase III trial of ...... outhwest Oncology Group trial.
@en
P2093
A J Wozniak
C A Presant
C M Moinpour
D R Gandara
P K Grevstad
P304
P356
10.1200/JCO.2001.19.13.3210
P407
P577
2001-07-01T00:00:00Z